192 related articles for article (PubMed ID: 29962407)
1. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
[TBL] [Abstract][Full Text] [Related]
2. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
[TBL] [Abstract][Full Text] [Related]
3. Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors.
Sugiyama T; Asai T; Nedachi YM; Katanasaka Y; Shimizu K; Maeda N; Oku N
PLoS One; 2013; 8(6):e67550. PubMed ID: 23840738
[TBL] [Abstract][Full Text] [Related]
4. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
6. Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation.
Ding Y; Ji T; Zhao Y; Zhang Y; Zhao X; Zhao R; Lang J; Zhao X; Shi J; Sukumar S; Nie G
Mol Cancer Ther; 2015 Oct; 14(10):2390-400. PubMed ID: 26269603
[TBL] [Abstract][Full Text] [Related]
7. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
8. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
Scherzinger-Laude K; Schönherr C; Lewrick F; Süss R; Francese G; Rössler J
Int J Nanomedicine; 2013; 8():2197-211. PubMed ID: 23818777
[TBL] [Abstract][Full Text] [Related]
10. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
12. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
13. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
Gu Z; Chang M; Fan Y; Shi Y; Lin G
Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo.
Kluza E; Jacobs I; Hectors SJ; Mayo KH; Griffioen AW; Strijkers GJ; Nicolay K
J Control Release; 2012 Mar; 158(2):207-14. PubMed ID: 22079810
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
16. Advances in an active and passive targeting to tumor and adipose tissues.
Sakurai Y; Kajimoto K; Hatakeyama H; Harashima H
Expert Opin Drug Deliv; 2015 Jan; 12(1):41-52. PubMed ID: 25376864
[TBL] [Abstract][Full Text] [Related]
17. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
18. A photo-responsive peptide- and asparagine-glycine-arginine (NGR) peptide-mediated liposomal delivery system.
Xie X; Yang Y; Yang Y; Zhang H; Li Y; Mei X
Drug Deliv; 2016 Sep; 23(7):2445-2456. PubMed ID: 25693640
[TBL] [Abstract][Full Text] [Related]
19. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
20. Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes.
Guo Z; Li W; Yuan Y; Zheng K; Tang Y; Ma K; Cui C; Wang L; He B; Zhang Q
Drug Deliv; 2018 Nov; 25(1):112-121. PubMed ID: 29260912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
